A s the interface between the gut lumen and the body, the intestinal epithelial layer is continuously exposed to large numbers of microbial and dietary antigens. Consequently, intestinal homeostasis requires sophisticated immune networks that effectively clear pathogenic microbes while maintaining tolerance to harmless antigens. To achieve this balance, intraepithelial lymphocytes (IELs) that are scattered among intestinal epithelial cells carry out numerous important functions. 1 Most IELs are a heterogeneous population of T lymphocytes, including both TCRαβ + and TCRγδ + IELs. Unlike T cells in other tissues, most TCRαβ + IELs in the small intestine belong to the CD8 + subset. 2 Moreover, a sizeable fraction of these TCRαβ + IELs are CD4 − CD8α + CD8β − cells, 3 which are referred to as CD8αα IELs based on their expression of the CD8αα homodimer.
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CD8αα IELs are distinct from conventional T cells in several aspects. For example, CD8αα IELs exhibit a self-reactive TCR repertoire, lack expression of some surface markers that are typically expressed by conventional T cells, and express natural killer (NK) cell receptors such as NK1.1 and Ly49 molecules. 1 Moreover, similar to a recently identified ILC1 subset, CD8αα IELs require the transcription factor T-bet for development, 4, 5 and constitutively express CD69, a molecule associated with cell activation and tissue residency. 6 Although the phenotype and function of CD8αα IELs have been well characterized, the origin and development of CD8αα IELs have not been fully investigated. Early studies suggest that CD8αα IELs may develop locally in the intestine; 1,7 however, compelling evidence from recent studies supports a thymic origin for CD8αα IELs. [8] [9] [10] It has been increasingly appreciated that CD8αα IELs develop from CD4 and CD8 double-negative (DN) thymocytes through strong recognition of thymic self-ligands. [8] [9] [10] More recently, a study published in Nature Immunology by Ruscher et al. 11 described two distinct populations of CD8αα IEL precursors (IELps) in the thymus.
As previous studies have found that IELps are concentrated in thymic TCRβ + CD5 + CD4 − CD8 − cells, 8, 9 Ruscher et al. 11 initially excluded invariant NKT cells using CD1d tetramers and CD25 + regulatory T cells, and then gated TCRβ + CD5 + CD4 − CD8 − cells for further analysis. 11 The authors showed that these thymic DN T cells partially express the mature markers CD122 and the MHC class I molecule H-2K b , and form two distinct populations, which are termed 'type A' IELps and 'type B' IELps, respectively, based on T-bet and PD-1 expression. Type A IELps are PD-1 positive but do not express T-bet. 11 By contrast, type B IELps are PD-1 − T-bet + and express NK1.1 and IFN-γ, which are not expressed by type A IELps. 11 Using spanning-tree analysis, the authors found that type A IELps are located in the thymic CD4 single-positive (SP) cell branch and that type B IELps emerged near the CD4 and CD8 double-positive (DP) progenitor group. Moreover, only type B IELps express the activation and memory marker CD44 and the chemokine receptor CXCR3, while both cell types are negative for CCR7. 11 11 These findings raised the question of whether type B IELps develop from type A IELps. To this end, the authors performed 'time-stamp' experiments using Cd4 creERT2 × Rosa26 floxedSTOPTdT mice, in which cells expressing CD4 and their progeny could be labeled with tdTomato at the time of exposure to tamoxifen. Surprisingly, while the frequency of labeled type A IELps peaked on day 5 and dramatically decreased 10 days after tamoxifen injection, type B IELps were not labeled in this period. 11 Therefore, it is likely that type A IELps exit directly from the thymus without differentiation into type B IELps. Moreover, the differences in MHC restriction and TCR use between type A IELps and type B IELps further suggests that these IELps may represent two developmentally separate subsets. 11 Differential expression of homing molecules between these IELp populations led to the investigation of their location within the thymus and migration properties. Using immunofluorescence-based quantitative histocytometry, Ruscher et al. found that 70% of type A IELps are located in the cortex, while 80% of type B IELps were found in the medulla (Figure 1 ). Further analysis shows that the G-protein-coupled receptor S1PR1 and its related transcription factor KLF2, which are required for lymphocyte egress from tissues, 12, 13 are preferentially expressed by type A IELps. Consistent with this finding, type A IELps rather than type B IELps are the main population migrating from the thymus to the periphery, which is supported by the enrichment of type A IELps among the recent thymic emigrants (RTEs), and the emigration of type A IELps is dependent on S1PR1. 11 This new study by Ruscher et al. highlights that the two distinct populations of thymic mature DN T cells have the potential to selectively develop into CD8αα IELs. Despite their similarities in developmental potential, the two subtypes of IELps identified in this study are different in maturation status, thymic location, migration efficiency, and antigen-receptor specificities. However, it remains unclear whether these distinct IELps generate phenotypically and/or functionally different CD8αα IEL subsets. Moreover, while the migration of type A IELps in an S1PR1-dependent manner has been demonstrated, the mechanism underlying type B IELps egress from the thymus has not been investigated. Overall, exploring the origin and characteristics of IELps provides new insights into the heterogeneity of IELs and also helps to understand the functionality of different IEL subsets. Figure 1 The origin and development of intestinal CD8αα IELs. In the thymus, CD4 and CD8 double-negative (DN) thymocytes give rise to CD4 and CD8 double-positive (DP) thymocytes. Through positive selection, DP thymocytes further differentiate into CD8αβ + or CD4 + singlepositive (SP) cells. DP thymocytes can also undergo alternative selection and downregulate the expression of CD4 and CD8, becoming the precursors of CD8αα IELs. There are two distinct subsets of CD8αα IEL precursors (IELps) in the thymus: one subset is PD1 + T-bet − (type A IELps), which localizes to the thymic cortex and efficiently emigrates in an S1PR1-dependent manner, while the other is PD1 − T-bet + (type B IELps), which localizes to the thymic medulla and is less migration-competent.
